Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).
Hayato KawachiTadaaki YamadaAkihiro YoshimuraKenji MorimotoMasahiro IwasakuShinsaku TokudaYoung Hak KimTakayuki ShimoseKoichi TakayamaPublished in: Therapeutic advances in medical oncology (2023)
This trial was registered with the Japan Registry for Clinical Trials on 12 January 2023 (jRCTs 051220149).